Kimmtrak(tebentafusp)
Kimmtrak (tebentafusp) is a protein pharmaceutical. Tebentafusp was first approved as Kimmtrak on 2022-01-25. It has been approved in Europe to treat uveal neoplasms.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Kimmtrak
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tebentafusp
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Kimmtrak | tebentafusp-tebn | Immunocore | N-761228 RX | 2022-01-25 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kimmtrak | Biologic Licensing Application | 2022-02-21 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
tebentafusp, Kimmtrak, Immunocore Limited | |||
| 2029-01-25 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | 3 | 4 | 1 | — | — | 6 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uveal neoplasms | D014604 | EFO_1001230 | 1 | 3 | — | — | 1 | 4 | |
| Neoplasms | D009369 | C80 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TEBENTAFUSP |
| INN | tebentafusp |
| Description | Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer). Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. Tebentafusp is given by intravenous infusion.
|
| Classification | Protein |
| Drug class | fusion proteins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1874157-95-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297990 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15283 |
| UNII ID | N658GY6L3E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 285 documents
View more details
Safety
Black-box Warning
Black-box warning for: Kimmtrak
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more